Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Landmark Trial for...

    Landmark Trial for Dapagliflozin: AstraZeneca diabetes drug Forxiga shows benefits in patients with heart failure

    Farhat NasimWritten by Farhat Nasim Published On 2019-09-06T09:17:13+05:30  |  Updated On 6 Sept 2019 9:17 AM IST
    Landmark Trial for Dapagliflozin: AstraZeneca diabetes drug Forxiga shows benefits in patients with heart failure

    Dapagliflozin(Forxiga) is currently available and indicated for type 2 diabetes in India and not yet approved for treatment for heart failure in India.


    New Delhi: AstraZeneca recently announced detailed results from the landmark Phase III DAPA-HF trial for Forxiga (dapagliflozin) that showed the medicine on top of standard of care reduced both the incidence of cardiovascular death and the worsening of heart failure.


    DAPA-HF is the first outcomes trial with an SGLT2 inhibitor investigating the treatment of heart failure in patients with reduced ejection fraction (HFrEF), with and without type-2 diabetes (T2D). Forxiga is currently approved to treat patients with T2D.


    Forxiga is a first-in-class, oral once-daily SGLT2 inhibitor indicated as both monotherapy and as part of combination therapy to improve glycaemic control, with the additional benefits of weight loss and blood pressure reduction, as an adjunct to diet and exercise in adults with T2D.

    Topline results announced in August 2019 showed DAPA-HF met the primary endpoint. The detailed results of the trial presented recently at the ESC Congress 2019 in Paris, France, showed Forxiga reduced the composite of cardiovascular (CV) death or worsening of heart failure by 26% (p<0.0001) and showed a reduction in each of the individual components of the composite endpoint.


    Commenting on the same, Mene Pangalos, Executive Vice President, BioPharmaceuticals RnD, said, “Forxiga is well
    established in the treatment of type-2 diabetes, and these exciting new findings offer clinically meaningful insights into the potential of the medicine to reduce the burden of heart failure in patients with and without type-2 diabetes. We are proud to be contributing to the scientific body of evidence during the ESC Congress 2019.”


    Also Read: AstraZeneca gets EU nod to diabetes drug Forxiga

    John McMurray, MD, University of Glasgow, Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, said, “We are very pleased that Forxiga was so effective in our trial – it did all the things we would like any drug to do in heart failure, which is to improve symptoms, reduce hospital admissions and increase survival. Even better, Forxiga was as effective in heart failure patients without diabetes as in those with diabetes.”


    In analysing each of the components of the primary composite endpoint, there was a 30% decrease (p<0.0001) in the risk of experiencing a first episode of worsening heart failure and an 18% decrease (p=0.0294) in the risk of dying from cardiovascular causes. The effect of Forxiga on the primary composite endpoint was generally consistent across the key subgroups examined.


    Heart Failure affects approximately 64 million people worldwide, with at least 8–10 million patients with Heart Failure in India 1. Heart Failure is the first complication of type 2 diabetes-related Cardiovascular disease presenting high mortality risk. 40.4% of Asian patients with Heart failure has an underlying type 2 diabetes 2.


    As per Global data, nearly 50% of patients diagnosed with Heart Failure succumb within 5 years of diagnosis 2,3,4 HF remains as ‘malignant’ as some of the most common cancers in both men (prostate and bladder cancers) and women (breast cancers). 5 Further heart failure strikes Indians young, a decade younger than their western counterparts 3.


    Dr Balbir Singh, Chairman, Interventional Cardiology and Electrophysiology, Medanta Hospital commenting on the new findings said“ At least 68 per cent of people aged 65 or older with diabetes die from some form of heart disease. Adults with diabetes are two to four times more likely to die from heart disease than adults without diabetes. The success of this decade has been newer drugs which not only control diabetes but also reduce deaths from
    heart disease particularly heart failure”.


    The safety profile of Forxiga in the DAPA-HF trial was consistent with the well-established safety profile of the medicine. The proportion of patients with volume depletion (7.5% versus 6.8%) and renal adverse events (6.5% vs 7.2%), which are common of concern when treating heart failure, were comparable to placebo. Major hypoglycaemic events (0.2% versus 0.2%) were rare in both treatment groups.


    Dapagliflozin(Forxiga) is currently available and indicated for type 2 diabetes in India and not yet approved for treatment for heart failure in India.


    Forxiga has a robust programme of clinical trials that includes more than 35 completed and ongoing Phase IIb/III trials in more than 35,000 patients, as well as more than 2.5 million patient-years’ experience.

    Asian PatientsAstraZenecacancercardiac arrestCardiovascular Researchclinical trailDapagliflozindiabetes drugdiabetes treatmentForxigaforxiga trialheart attckHeart failure drugheart patientIndiaIndianMedantamonotherapypharmapharma newspharma news indiaphase 3 trialSGLT2 InhibitorT2Dtype-2 diabetes

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok